Loading…
Amneal Pharmaceuticals, Inc. is projected to rise to $24.88 by 2027, a +34% move from its current price of $18.50. AMRX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $18.16 | $18.51 | $18.87 | +0.06% |
| Aug 2 | $18.03 | $18.52 | $19.03 | +0.11% |
| Aug 3 | $17.93 | $18.53 | $19.15 | +0.17% |
| Aug 4 | $17.85 | $18.54 | $19.26 | +0.22% |
| Aug 5 | $17.78 | $18.55 | $19.36 | +0.28% |
| Aug 6 | $17.71 | $18.56 | $19.45 | +0.33% |
| Aug 7 | $17.66 | $18.57 | $19.53 | +0.39% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.66 | $18.57 | $19.53 | +0.39% |
| Week 2 | $17.36 | $18.64 | $20.02 | +0.77% |
| Week 3 | $17.15 | $18.72 | $20.42 | +1.16% |
| Week 4 | $16.99 | $18.79 | $20.78 | +1.56% |
| Week 5 | $16.85 | $18.86 | $21.11 | +1.95% |
| Week 6 | $16.73 | $18.93 | $21.42 | +2.34% |
| Week 7 | $16.63 | $19.01 | $21.72 | +2.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, including immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
The Specialty segment focuses on central nervous system and endocrine disorders, including Parkinson's disease, and provides products such as Rytary, Unithroid, ONGENTYS, and CREXONT for related conditions. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs, distributing bottles and unit dose pharmaceuticals and packaging and distributing pharmaceuticals and vitamins to retail and institutional customers. Amneal was founded in 2002 and is headquartered in Bridgewater, New Jersey; it was formerly known as Atlas Holdings, Inc.
and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
Amneal Pharmaceuticals, Inc. (AMRX) is a healthcare stock currently trading at $18.76 with a market cap of $5.99B and a market rank of 1206.
The current price sits within a broader forecast landscape that projects gradual to substantial upside over time, with the near term showing a neutral stance and later years turning bullish. As of now, the 30-day technical picture shows a bullish tilt supported by momentum and price structure.
The multi-year forecast outlines a rising average price path, reaching $387.52 on average by 2050, with a maximum projected price of $633.45 and a minimum of $256.68 in 2050, signaling strong long-term upside while acknowledging inherent uncertainty in predictions.
A major floor 36.2% below — a decisive break under it would weaken the trend.
The nearest floor, 12.9% below — buyers have tended to step in here.
The nearest ceiling, 3.2% above — a clean break opens room to run.
A major ceiling 12.9% above — clearing it would confirm fresh momentum.
Key AMRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.47 | Buy | $18.50 | Sell |
| MA 10 | $18.15 | Buy | $18.20 | Buy |
| MA 20 | $17.64 | Buy | $17.70 | Buy |
| MA 50 | $15.93 | Buy | $16.36 | Buy |
| MA 100 | $14.28 | Buy | $15.07 | Buy |
| MA 200 | $13.44 | Buy | $13.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.60 | Neutral |
| Stoch RSI (14) | 31.54 | Neutral |
| CCI (20) | 100.82 | Buy |
| Williams %R (14) | -24.90 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 10.84 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 75.10 | Neutral |
| TRIX (15) | 0.60 | Buy |
| Awesome (5,34) | 1.23 | Buy |
| Ultimate (7,14,28) | 60.62 | Neutral |
| Momentum (10) | 0.46 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 18.93 | Sell |
| ADX (14) | 36.92 | Buy |
| ATR (14) | 0.32 | Info |
The thirty-day range is $16.63–$21.16, reflecting near-term volatility within a defined band.
RSI14 sits at 70, and the stock trades above the 50-day simple moving average of $15.41 and the 200-day simple moving average of $13.27, indicating a bullish tilt in the near term.
Support is indicated at $16.11 and resistance at $18.10, framing the immediate technical landscape and potential turning points for the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.81 | $18.50 | $25.12 | 0% | Neutral | |
| $20.38 | $24.88 | $31.74 | +34% | Bullish | |
| $22.49 | $27.97 | $36.68 | +51% | Bullish | |
| $28.34 | $35.81 | $47.97 | +94% | Bullish | |
| $37.10 | $47.53 | $64.83 | +157% | Bullish | |
| $42.03 | $54.51 | $75.56 | +195% | Bullish | |
| $48.70 | $63.89 | $89.83 | +245% | Bullish | |
| $53.04 | $70.33 | $100.18 | +280% | Bullish | |
| $56.89 | $76.18 | $109.84 | +312% | Bullish | |
| $67.33 | $91.04 | $132.74 | +392% | Bullish | |
| $107.66 | $151.92 | $232.26 | +721% | Bullish | |
| $257.03 | $389.42 | $638.60 | +20.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.81 | $18.50 | $21.55 | +0.00% |
| August 2026 | $16.34 | $19.05 | $22.65 | +2.99% |
| September 2026 | $16.59 | $19.45 | $23.34 | +2.10% |
| October 2026 | $16.46 | $19.40 | $23.46 | -0.27% |
| November 2026 | $16.72 | $19.78 | $24.06 | +1.95% |
| December 2026 | $17.30 | $20.54 | $25.12 | +3.82% |
Click any year to see its month-by-month AMRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Amneal Pharmaceuticals, Inc.'s 2026 outlook centres on $18.50, within a $11.81 to $25.12 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AMRX could reach as high as $31.74, with a base case around $24.88 and support toward $20.38 — roughly +34% from $18.50. Momentum favours further upside here.
Expect AMRX to range from $22.49 to $36.68 through 2028. The $27.97 average target implies a +51% move from current prices. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The AMRX price prediction for 2029 points to an average of $35.81 (low $28.34, high $47.97) — a potential gain of +94% on today's $18.50. Momentum favours further upside here.
In 2030, AMRX is projected to trade between $37.10 and $64.83, averaging $47.53 — a potential gain of +157% from today's $18.50. That is up +33% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Amneal Pharmaceuticals, Inc.'s 2031 outlook centres on $54.51, within a $42.03 to $75.56 range. That is up +15% on the projected 2030 average. That marks a +195% change versus current levels. Momentum favours further upside here.
By 2032, AMRX could reach as high as $89.83, with a base case around $63.89 and support toward $48.70 — roughly +245% from $18.50. Buyers look set to stay in control over this stretch.
Expect AMRX to range from $53.04 to $100.18 through 2033. The $70.33 average target implies a +280% move from current prices. That is up +10% on the projected 2032 average. Momentum favours further upside here.
The AMRX price prediction for 2034 points to an average of $76.18 (low $56.89, high $109.84) — a potential gain of +312% on today's $18.50. Buyers look set to stay in control over this stretch.
In 2035, AMRX is projected to trade between $67.33 and $132.74, averaging $91.04 — a potential gain of +392% from today's $18.50. That is up +20% on the projected 2034 average. Momentum favours further upside here.
Amneal Pharmaceuticals, Inc.'s 2040 outlook centres on $151.92, within a $107.66 to $232.26 range. That is up +67% on the projected 2035 average. That marks a +721% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AMRX could reach as high as $638.60, with a base case around $389.42 and support toward $257.03 — roughly +20.0x from $18.50. Momentum favours further upside here.
Investing $1,000 in AMRX today (≈ 54.054054 AMRX) could be worth
$21,049.56
+$20,049.56 (+2005%) by 2050 · US Dollar
Based on the average projected AMRX price of $389.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMRXwould be worth at today's price.
$1,000 invested in AMRX on Jul 30, 2025 (≈ 123.915742 AMRX) would be worth
$2,292.44
+$1,292.44 (+129.2%) today · 2.29× · US Dollar
Based on a AMRX entry price of $8.07 vs. today's $18.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.97 | $1,029.49 | +2.9% |
| 1 month ago | $17.31 | $1,068.75 | +6.9% |
| 3 months ago | $12.83 | $1,441.93 | +44.2% |
| 6 months ago | $13.68 | $1,352.34 | +35.2% |
| 1 year ago | $8.07 | $2,292.44 | +129.2% |
| All time (5.0y) ago | $4.99 | $3,707.41 | +270.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMRX forecast.
Our base-case forecast reaches $37.00 around 2030.
Implied market cap at $37.00: $11.82B
Looking further out, the forecast shows a bullish trajectory across multiple years. The 2026 average price is $18.76 with a min of $11.81 and a max of $25.48, yielding a 0% ROI in that year and a neutral sentiment. By 2027, the average rises to $25.13, with a min of $20.60 and a max of $32.03, and a 34% ROI with bullish sentiment.
The path continues upward through 2028 (avg $28.30, min $22.77, max $37.06; ROI 50.8%), 2029 (avg $36.08, min $28.58, max $48.26; ROI 92.3%), and 2030 (avg $47.72, min $37.30, max $64.99; ROI 154.4%), all with bullish sentiment. In the following years, the forecast shows continued upside, reaching 2040 (avg $151.83, min $107.86, max $231.50; ROI 709.3%) and 2050 (avg $387.52, min $256.68, max $633.45; ROI 1965.7%).
Overall, the long-term outlook shows strong upside potential with rising average prices and high ROI projections, but these are estimates and come with uncertainty.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $47.72, with a minimum of $37.30 and a maximum of $64.99; the ROI is 154.4% and sentiment is BULLISH.
From 2027 onward the forecast shows bullish sentiment, with rising average prices (2027 avg $25.13, 2028 avg $28.30, 2029 avg $36.08) and notable ROI (34%, 50.8%, 92.3%), indicating substantial upside potential according to the forecast.
Yes, the forecast projects a max of $100.31 in 2033.
The 2040 forecast shows min $107.86, avg $151.83, max $231.50; ROI 709.3%; sentiment BULLISH.
Current price is $18.76 and market cap is $5.99B.
Amneal Pharmaceuticals, Inc. Community Discussion
0Share your Amneal Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.